论文部分内容阅读
本品系一口服和注射均有效的血管紧张素转换酶抑制剂,美国食品药品管理局于1982年1月批准本品上市,用于治疗高血压,于同年10月又批准该药用于治疗心衰。国内于1978年由上海医药工业研究院研制成功,并于1980年转让给常州药厂,于1983年7月通过了鉴定。药理作用:本品具降压作用,其作用机理为:(1)竞争性地抑制血管紧张素转换酶,阻断血管紧张素Ⅱ的生成,从而抑制血管收缩,并使醛固酮的分泌减少。(2)抑制激肽酶Ⅱ,使激肽积聚,促使血管扩张。(3)使前列腺素的代谢
This strain of oral and effective injection of angiotensin-converting enzyme inhibitors, the FDA approved the FDA in January 1982 listing for the treatment of high blood pressure, in October the same year and approved the drug for treatment Heart failure. Domestic in 1978 by the Shanghai Institute of Pharmaceutical Industry successfully developed and transferred in 1980 to Changzhou Pharmaceutical Factory, in July 1983 passed the appraisal. Pharmacological effects: The goods with antihypertensive effect, its mechanism of action: (1) competitive inhibition of angiotensin converting enzyme, blocking the formation of angiotensin Ⅱ, thereby inhibiting vasoconstriction, and reduce the secretion of aldosterone. (2) inhibition of kininase Ⅱ, the accumulation of kinin to promote vasodilation. (3) Prostaglandin metabolism